Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 33

1.

A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma.

Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L, Haugen BR, Sherman SI, Cooper DS, Braunstein GD, Lee S, Davies TF, Arafah BM, Ladenson PW, Pinchera A.

J Clin Endocrinol Metab. 2003 Apr;88(4):1433-41. Review.

PMID:
12679418
2.

Recombinant human thyrotropin (rhTSH) in the follow-up and treatment of patients with thyroid cancer.

Bombardieri E, Seregni E, Villano C, Aliberti G, Mattavelli F.

Tumori. 2003 Sep-Oct;89(5):533-6. Review.

PMID:
14870779
3.

Follow-up of differentiated thyroid carcinoma.

Pagano L, Klain M, Pulcrano M, Angellotti G, Pasano F, Salvatore M, Lombardi G, Biondi B.

Minerva Endocrinol. 2004 Dec;29(4):161-74. Review. English, Italian.

4.
5.

Clinical experience with recombinant human thyroid-stimulating hormone (rhTSH): serum thyroglobulin measurement.

Pacini F, Lippi F.

J Endocrinol Invest. 1999;22(11 Suppl):25-9. Review.

PMID:
10727002
6.

Detection of residual and recurrent differentiated thyroid carcinoma by serum thyroglobulin measurement.

Spencer CA, LoPresti JS, Fatemi S, Nicoloff JT.

Thyroid. 1999 May;9(5):435-41. Review.

PMID:
10365673
7.

Papillary thyroid cancer: medical management and follow-up.

Kloos RT.

Curr Treat Options Oncol. 2005 Jul;6(4):323-38. Review.

PMID:
15967085
8.

The role of recombinant thyroid-stimulating hormone (rhTSH) in the detection and management of well-differentiated thyroid carcinoma: a roundtable discussion.

Schlumberger MJ, Incerti C, Pacini F, Reiners C.

J Endocrinol Invest. 1999;22(11 Suppl):35-41. Review.

PMID:
10727004
9.

Diagnostic and therapeutic use of recombinant human TSH (rhTSH) in differentiated thyroid cancer.

Pacini F, Castagna MG.

Best Pract Res Clin Endocrinol Metab. 2008 Dec;22(6):1009-21. doi: 10.1016/j.beem.2008.09.014. Review.

PMID:
19041828
10.

[Recombinant human TSH use in differentiated thyroid cancer].

Graf H, Paz-Filho G.

Arq Bras Endocrinol Metabol. 2007 Jul;51(5):806-12. Review. Portuguese.

11.
12.

Recombinant human thyroid-stimulating hormone (rhTSH): clinical development.

Incerti C.

J Endocrinol Invest. 1999;22(11 Suppl):8-16. Review.

PMID:
10727000
13.

Diagnostic follow-up of well-differentiated thyroid carcinoma: historical perspective and current status.

Schlumberger MJ.

J Endocrinol Invest. 1999;22(11 Suppl):3-7. Review.

PMID:
10726999
14.
15.
16.

Thyroglobulin measurement using highly sensitive assays in patients with differentiated thyroid cancer: a clinical position paper.

Giovanella L, Clark PM, Chiovato L, Duntas L, Elisei R, Feldt-Rasmussen U, Leenhardt L, Luster M, Schalin-Jäntti C, Schott M, Seregni E, Rimmele H, Smit J, Verburg FA.

Eur J Endocrinol. 2014 Aug;171(2):R33-46. doi: 10.1530/EJE-14-0148. Epub 2014 Apr 17. Review.

17.

Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective.

Schlumberger M, Berg G, Cohen O, Duntas L, Jamar F, Jarzab B, Limbert E, Lind P, Pacini F, Reiners C, Sánchez Franco F, Toft A, Wiersinga WM.

Eur J Endocrinol. 2004 Feb;150(2):105-12. Review.

19.

An overview of the management of papillary and follicular thyroid carcinoma.

Mazzaferri EL.

Thyroid. 1999 May;9(5):421-7. Review.

PMID:
10365671
20.

Supplemental Content

Support Center